GSK shares fell more than 5% after U.S. health officials narrowed their recommendation of respiratory syncytial virus vaccines to a smaller age range and more at-risk patients.
Related Posts
Activist Investor Doubles Down on Calls for Executive Changes at BP
U.K. activist investor Bluebell Capital Partners is pushing BP to remove its chairman and lead independent director.
How Booming Electricity Demand Is Stalling Efforts to Retire Coal and Gas
Companies are redoing the math behind the green-energy transition amid the rise of AI data centers.
The Jobs Where You Can Still Land a Signing Bonus
Job offers this fall are going to mission critical hires. If you get one, recruiters say you have leverage.